Capecitabine: Expanding options for the treatment of patients with early or locally advanced breast cancer

Oncologist

Volumn 11, Issue SUPPL. 1, 2006, Pages 20-26

  Wardley, Andrew ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Capecitabine; Docetaxel; Early breast cancer; Neoadjuvant

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; CONJUNCTIVITIS; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; EVIDENCE BASED MEDICINE; FEMALE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; DEOXYCYTIDINE; EVIDENCE-BASED MEDICINE; FEMALE; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING;

EID: 34447319255     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-90001-20     Document Type: Conference Paper

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
2. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and florouracil node-positive breast cancer. The results of 20 years of follow-up N Engl J Med 1995;332:901-906
3. Van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemo therapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol2001;19:4224-4237.
4. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast can cer. J Clin Oncol 2003;21:3357-3365.
5. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert OpinPharmacother 2005;6:1477-1491.
6. Kaufmann M, von Minckwitz G. Smith R et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 2003;21:2600-2608.
7. Sledge GW Jr. Preoperative chemotherapy for breast cancer: lessons learned and future prospects. J Clin Oncol 2003;21:4481-4482.
8. Bear HD. Anderson S. Smith RE et al. Arandomized trial comparing pre operative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) Tin patients (pts) with operable carcinoma of the breast: results of NSABPB-27. Breast Cancer Res Treat 2004;88(suppl 1):S16.
9. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313.
10. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pre-treated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
11. Beslija S, Obralic N, Basic H et al. A single institution randomized trial of Taxotere (T) and Xeloda (X) given in combination vs. Taxotere (t) followed by Xeloda (x) after progression as first line chemotherapy (CT) for metastatic breast cancer (MBC). EJC Suppl 2005;3(suppl):114.
12. Lee KS, Lee ES, Kwon YM et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breastcancer(BC). Breast Cancer Res Treat 2005;94(suppl 1):S224.
13. Mansutti M, Fasola G, Cavazzini Getal. Randomized phase III trial com paring TEX (docetaxel, epirubicin and capecitabine) vs. TE (docetaxel and epirubicin) in advanced breast cancer patients: findings from the 2nd interim analysis. Ann Oncol 2004; 15(suppl 3):iii42.
14. von Minckwitz G, Blohmer JU, Loehr A et al. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemo therapy - first results of the phase III GEPARTRIO-Study by the German Breast Group. Breast Cancer Res Treat 2005;94(suppl 1):S19.
15. Lebowitz PF, Eng-Wong J, Swain SM et al. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Can cer Res 2004;10:6764-6769.
16. Bellet M, Muñoz M, Suárez M et al. Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (III A and IIIB stage). Correlation between clinico-pathological response and fluoropyrimidine-enzyme profile. Early results. J Clin Oncol (Meeting Abstracts) 2005;23:61s.
17. Lybaert W, Wildiers H, Neven P et al. Neoadjuvant capecitabine (X) plus docetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): preliminary safety and efficacy data. EJC Suppl 2005;3:105.
18. Franco SX, Perez A. Frankel C et al. Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). J Clin Oncol (Meeting Abstracts) 2005;23:96s.
19. Lu YS, Kuo SH. Su WP et al. A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol (Meeting Abstracts) 2005;23:93s.
20. Perez-Manga G. Mendez M, Palomero MI et al. Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast can cer. EJC Suppl 2005;3:133.
21. Ahlgren J, Lidbrink E, Lind B et al. Phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in women with locally advanced or inflammatory breast cancer. Proc Am Soc Clin Oncol 2003;22:27.
22. Gaui MF, Amorim G, Pereira G et al. Neoadjuvant capecitabine chemoradiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy: findings from a prospective phase II trial. Breast Cancer Res Treat 2005;94(suppl 1):S227.
23. Joensuu H. Hemminki A, Tanner M et al. Phase III. randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C. + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast can cer (BC): an interim safety analysis. J Clin Oncol (Meeting Abstracts) 2005;23:57s.
24. Talbot DC, Moiseyenko V, Van Belle S et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
25. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
26. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
27. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-1768.
28. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
29. Fumoleau P. Largillier R, Clippe C et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and tax-ane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-542.
30. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.